Low molecular weight heparin and atherosclerosis

被引：0
作者：
Hunt D. [1 ]
机构：
[1] Section of General Internal Medicine, Ben Taub General Hospital, Houston, TX 77030
来源：
Current Atherosclerosis Reports | 2004年 / 6卷 / 2期
关键词：
Percutaneous Coronary Intervention; Acute Coronary Syndrome; Enoxaparin; Abciximab; Unfractionated Heparin;
D O I：
10.1007/s11883-004-0103-9
中图分类号：
学科分类号：
摘要：
Low molecular weight heparin (LMWH) has dramatically impacted the treatment of venous thromboembolic disease and acute coronary syndromes. Recent studies help define the role of these agents for patients undergoing percutaneous coronary interventions and for patients treated with thrombolytic agents for ST-segment elevation myocardial infarction. Recent studies also suggest potential usefulness of LMWH for patients with peripheral vascular disease and its limits of utility in stroke. This review summarizes the evidence about the use of LMWH in these clinical situations. Copyright © 2004 by Current Science Inc.
引用
收藏
页码：140 / 147
页数：7
相关论文
共 46 条
[41]  
Bath P.M., Lindenstrom E., Boysen G., Et al., Tinzaparin in acute ischaemic stroke (TAIST): A randomised aspirin-controlled trial, Lancet, 358, pp. 702-710, (2001)
[42]  
Edmondson R.A., Cohen A.T., Das S.K., Et al., Low-molecular weight heparin versus aspirin and dipyridamole after femoropoliteal bypass grafting, Lancet, 344, pp. 914-918, (1994)
[43]  
Logason K., Bergqvist D., Low molecular weight heparin (enoxaparin) versus dextran in the prevention of early occlusion following arterial bypass surgey distal to the groin, Eur. J. Vasc. Endovasc. Surg., 21, pp. 261-265, (2001)
[44]  
Shammas N.W., Lemke J.H., Dippel E.J., Et al., In-hospital complications of peripheral vascular interventions using unfractionated heparin as the primary anticoagulant, J. Invasive Cardiol., 15, pp. 242-246, (2003)
[45]  
Schweizer J., Muller A., Forkmann L., Et al., Potential use of a low-molecular-weight heparin to prevent restenosis in patients with extensive wall damage following peripheral angioplasty, Angiology, 52, pp. 659-669, (2001)
[46]  
Strecker E.P., Gottmann D., Boos I.B., Vetter S., Low-molecular-weight heparin (reviparin) reduces the incidence of femoropopliteal in-stent stenosis: Preliminary results of an ongoing study, Cardiovasc. Intervent. Radiol., 21, pp. 375-379, (1998)
12345